Ionis and Akcea get their shot at competing with Alnylam for a rare disease group — but it’s not expected to be pretty
Ionis $IONS and Akcea $AKCA have been given a green light to go head-to-head into a marketing fight with Alnylam for treating extremely rare cases of TTR amyloidosis — with one arm tied behind their back on efficacy and both commercial feet hobbled by a worrisome safety issue.
Akcea — a spinout from Ionis, which still controls a majority of the company — put out the word of the delayed OK for Tegsedi (inotersen) on Friday night, which comes after a regulatory delay that put them one step behind the competition.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.